School of Medicine
Showing 1-6 of 6 Results
Joseph (Joe) Lipsick
Professor of Pathology, of Genetics and, by courtesy, of Biology
Current Research and Scholarly Interests Function and evolution of the Myb oncogene family; function and evolution of E2F transcriptional regulators and RB tumor suppressors; epigenetic regulation of chromatin and chromosomes; cancer genetics.
Jonathan Z. Long
Assistant Professor of Pathology
Current Research and Scholarly Interests My laboratory seeks to discover new bioactive metabolite signaling pathways that control mammalian metabolism and physiology. Our unique and multidisciplinary approach combines synthetic chemistry, biochemistry, mass spectrometry, and genetics to chart functionally relevant regions of unannotated biochemical space. In recent years, we have mapped entire branches of previously unknown bioactive metabolites and identified their functions. These discoveries include a circulating PM20D1/N-acyl amino acid pathway in blood and a MAGL-controlled lipid signaling pathway in the brain. Ultimately, we hope to translate these findings into pharmacologically tractable opportunities (e.g., enzyme inhibitors, transporter antagonists, or receptor modulators) for therapeutic intervention in cardiometabolic disease.
Steven Ramsey Long
Clinical Professor, Pathology
Bio Dr. Long obtained dual undergraduate degrees in Economics and Art History from Stanford prior to enrolling at UCSF where he completed his MD, a post-sophomore fellowship in Pathology, residency in Anatomic Pathology, a Fellowship in Surgical Pathology, and Clinical Instructorship in Cytopathology.
He then spent sixteen years in community practice honing his expertise in fine needle aspiration, cytopathology, and surgical pathology. Dr. Long was one of the first pathologists to pioneer the use of ultrasound guided fine needle aspiration biopsies in an outpatient clinic setting, helping to establish USFNA as a core component to contemporary cytopathology practices. During this time he also gained valuable leadership and business experience including directing two cytopathology laboratories, overseeing billing and outreach operations, and serving four consecutive terms as president of one of the largest community practice groups in California (serving 10 locations, two large clinical labs, 7 area hospitals, and providing services for over 150,000 anatomic pathology specimens/yr).
Dr. Long returned to Stanford in 2012 to join the Department of Pathology in the sections of Cytopathology and Surgical Pathology. He has been active teaching USFNA, cytopathology, and surgical pathology to residents and fellows and his research interests primarily focus on expanding and refining the role of fine needle aspiration in supporting diagnosis, precision medicine, and clinical trial research. He is currently collaborating in several clinical trials involving CarT cell therapies, and immunoncology studies for lymphoma.
His current administrative roles include: Director of Anatomic Pathology, Director of Surgical Pathology, Director of the Histology Laboratory, Co-Director of the Immunohistochemistry Laboratory, and Medical Director of the Cancer Center South Bay (CCSB), in Los Gatos, CA. In these roles he has helped lead the Surgical Pathology section to move from a general service to one that now includes sub-specialty sections in: gastrointestinal, gynecologic, breast, head and neck, genitourinary, and pediatric pathology. The Surgical Pathology consultation service was also sub-specialized and the AP residency program was entirely re-worked to take advantage of the newly created subspecialty formats.
Dr. Long is currently the department?s physician improvement leader for the newly launched Improvement Capability Development Program (ICDP) at Stanford Medicine. This major initiative between the School of Medicine and Stanford Hospital and Clinics is designed to promote significant improvement projects and skills training in quality improvement and quality leadership. Our current initiative focuses on improving the efficiency, turn around time, and consistency of our AP operational units including: accessioning, grossing, and histology.
From May 2016 ? Nov 2017 Dr. Long participated in the second cohort of the Stanford Medicine Leadership Academy (SMLA). This intensive and rigorous eighteen-month leadership course was designed to prepare our 15-member cohort for advanced leadership roles both at Stanford Medicine and beyond. Participants received training coursework from Business School faculty in: Negotiation, Strategy, Difficult Conversations and Conflict Resolution, Scaling, Finance, Interpersonal Communications, as well as in depth 360 analysis, and Myers-Briggs testing. Each member was assigned an executive coach, and mentor, and was required to initiate and complete a strategic initiative. Other elements of the course included leadership interviews, attendance at two Stanford Medicine leadership retreats, and our mid-term SMLA retreat. A link describing the program can be found at: http://med.stanford.edu/smla/About.html. And a video of the SMLA cohort 2 discussing their leadership experiences can be viewed here: https://stanfordmedicine.app.box.com/v/SMLA2/file/249325043444
Teri A Longacre
Professor of Pathology (Research) at the Stanford University Medical Center
Current Research and Scholarly Interests Gynecological, breast and gastrointestinal pathology with major emphasis on ovarian cancer and ovarian tumors of low malignant potential. Pathology of familial and hereditary breast-ovarian-GI cancer.
Professor of Pathology
Current Research and Scholarly Interests We are interested in understanding how neural stem cells balance their self-renewal and differentiation and how deregulation of this process can result in brain tumor. We are also interested in mechanisms of neurodegeneration in Alzheimer’s and Parkinson’s diseases. We are using both Drosophila and mammalian models to address these fundamental questions.